Drew Rasco

8.5k citations
195 papers · 4.3k · 4 hit papers · h-index 33

Impact in

  • Oncology top 1%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
  • Immunology top 5%
    • Immunotherapy and Immune Responses
    • Immune Cell Function and Interaction

Papers in

    • Cancer Immunotherapy and Biomarkers 53
    • Cancer Treatment and Pharmacology 15
    • CAR-T cell therapy research 14

Drew Rasco

186 papers receiving 4.2k citations

Drew Rasco's Hit Papers

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ 2021 · 209 citations
2090+4+9Years since publication100200300

Peers

Drew Rasco
Comparison fields: 5 of 96
  • Oncology 2.1k
  • Immunology 800
  • Cancer Research 434
  • Pulmonary and Respiratory Medicine 805
  • Molecular Biology 1.7k
Replace Víctor Moreno with:
Víctor Moreno Spain
Andréa Varga France
Carlos Gomez‐Roca France
Juanita Lopez United Kingdom
Thomas A. Puchalski United States
Dimitrios Bafaloukos Greece
Ignacio Garrido‐Laguna United States
Silvana Del Vecchio Italy
J. Thaddeus Beck United States
Begoña Mellado Spain
Drew Rasco relative to Víctor Moreno Spain Víctor Moreno's profile →
Citations per field
00.5×1.5×1.9×
Víctor Moreno · 1×
Citations per year

Countries citing papers authored by Drew Rasco

Since Specialization
Citations

This map shows the geographic impact of Drew Rasco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Drew Rasco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Drew Rasco more than expected).

Fields of papers citing papers by Drew Rasco

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Drew Rasco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Drew Rasco. The network helps show where Drew Rasco may publish in the future.

Co-authors

The 25 scholars most cited alongside Drew Rasco, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Drew Rasco Line = papers co-authored together Drew Rasco links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 195 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Hit paper breakdown →
2019368
2
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Hit paper breakdown →
2012362
3
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Hit paper breakdown →
2020315
4
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
Hit paper breakdown →
2021209
5 2017191
6 2014132
7 2015126
8 2015105
9 2014104
10 201992
11 201780
12 201376
13 202075
14 201875
15 201473
16 201268
17 201367
18 202067
19 201966
20 201359

About Drew Rasco

Drew Rasco is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Immunology, having authored 195 papers that have together received 4.3k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (53 papers), Monoclonal and Polyclonal Antibodies Research (23 papers), Cancer Treatment and Pharmacology (15 papers), Advanced Breast Cancer Therapies (15 papers), Cancer Research and Treatments (15 papers), Chronic Lymphocytic Leukemia Research (15 papers), CAR-T cell therapy research (14 papers) and Radiopharmaceutical Chemistry and Applications (13 papers). The work is most often cited by research in Oncology (2.1k citations), Immunology (800 citations), Cancer Research (434 citations), Pulmonary and Respiratory Medicine (805 citations) and Molecular Biology (1.7k citations). Drew Rasco has collaborated with scholars based in United States, Spain and Australia. Frequent co-authors include Kyriakos P. Papadopoulos, Amita Patnaik, Anthony W. Tolcher, Matthew H. Taylor, Corina E. Dutcus, Daniel E. Stepan, Vicky Makker, Emmett V. Schmidt, Robert Shumaker and Muralidhar Beeram. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact